JP2020531043A5 - - Google Patents
Info
- Publication number
- JP2020531043A5 JP2020531043A5 JP2020520428A JP2020520428A JP2020531043A5 JP 2020531043 A5 JP2020531043 A5 JP 2020531043A5 JP 2020520428 A JP2020520428 A JP 2020520428A JP 2020520428 A JP2020520428 A JP 2020520428A JP 2020531043 A5 JP2020531043 A5 JP 2020531043A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- identity
- acid sequence
- amino acid
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762524554P | 2017-06-25 | 2017-06-25 | |
| US201762524557P | 2017-06-25 | 2017-06-25 | |
| US201762524558P | 2017-06-25 | 2017-06-25 | |
| US62/524,554 | 2017-06-25 | ||
| US62/524,558 | 2017-06-25 | ||
| US62/524,557 | 2017-06-25 | ||
| US201762545603P | 2017-08-15 | 2017-08-15 | |
| US62/545,603 | 2017-08-15 | ||
| US201762551035P | 2017-08-28 | 2017-08-28 | |
| US201762551032P | 2017-08-28 | 2017-08-28 | |
| US201762551065P | 2017-08-28 | 2017-08-28 | |
| US62/551,032 | 2017-08-28 | ||
| US62/551,035 | 2017-08-28 | ||
| US62/551,065 | 2017-08-28 | ||
| PCT/US2018/039155 WO2019005638A2 (en) | 2017-06-25 | 2018-06-22 | ANTI-4-1BB ANTIBODIES AND METHODS OF PREPARATION AND USE |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020531043A JP2020531043A (ja) | 2020-11-05 |
| JP2020531043A5 true JP2020531043A5 (enExample) | 2022-01-17 |
| JP7323513B2 JP7323513B2 (ja) | 2023-08-08 |
Family
ID=64742585
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020520426A Active JP7222987B2 (ja) | 2017-06-25 | 2018-06-22 | 抗ｒｏｒ１抗体とその作製及び使用方法 |
| JP2020520428A Active JP7323513B2 (ja) | 2017-06-25 | 2018-06-22 | 抗４－１ｂｂ抗体とその作製及び使用方法 |
| JP2023015342A Active JP7464764B2 (ja) | 2017-06-25 | 2023-02-03 | 抗ｒｏｒ１抗体とその作製及び使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020520426A Active JP7222987B2 (ja) | 2017-06-25 | 2018-06-22 | 抗ｒｏｒ１抗体とその作製及び使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023015342A Active JP7464764B2 (ja) | 2017-06-25 | 2023-02-03 | 抗ｒｏｒ１抗体とその作製及び使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11987635B2 (enExample) |
| EP (3) | EP3645741A4 (enExample) |
| JP (3) | JP7222987B2 (enExample) |
| CN (7) | CN116925227A (enExample) |
| ES (1) | ES3075567T3 (enExample) |
| WO (2) | WO2019005638A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201710836D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Car T-Cells |
| GB201710835D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Antibodies |
| GB201710838D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | Bispecific antibodies |
| WO2020018964A1 (en) | 2018-07-20 | 2020-01-23 | Fred Hutchinson Cancer Research Center | Compositions and methods for controlled expression of antigen-specific receptors |
| EP4097137A4 (en) * | 2020-01-30 | 2024-04-17 | Oncternal Therapeutics, Inc. | Combinations of egfr inhibitors and ror1 inhibitors for the treatment of cancer |
| JP7715722B2 (ja) * | 2020-02-28 | 2025-07-30 | 上海復宏漢霖生物技術股▲フン▼有限公司 | 抗ｃｄ１３７コンストラクト及びその使用 |
| CN111499746B (zh) * | 2020-04-28 | 2020-11-24 | 优睿赛思(武汉)生物科技有限公司 | 一种针对人白介素-2的高亲和力兔单克隆抗体及其应用 |
| EP4188430A4 (en) * | 2020-07-28 | 2024-11-06 | The Board Of Regents Of The University Of Texas System | Monoclonal antibodies against lilrb1 for diagnostic and therapeutic use |
| EP4209509A4 (en) * | 2020-09-03 | 2025-03-19 | Harbour Biomed (Shanghai) Co., Ltd | ROR1-TARGETTING ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, METHOD OF PREPARATION THEREOF AND USE THEREOF |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| CN115433277B (zh) * | 2021-06-05 | 2026-05-15 | 苏州缔码生物科技有限公司 | 抗cd38兔重组单克隆抗体的制备及应用 |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| CA3224492A1 (en) | 2021-07-19 | 2023-01-26 | Xiaojun Han | Immunoconjugates and methods |
| JP2024540099A (ja) | 2021-10-28 | 2024-10-31 | ライエル・イミュノファーマ・インコーポレイテッド | Ｒｏｒ１結合タンパク質を発現する細胞を培養する方法 |
| CN116333139B (zh) * | 2021-12-22 | 2026-02-27 | 上海复旦张江生物医药股份有限公司 | 一种抗fda0128抗体、其制备方法和应用 |
| WO2024064958A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
| WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| US20240294651A1 (en) | 2023-01-30 | 2024-09-05 | Kymab Limited | Antibodies |
| CN118745226B (zh) * | 2023-06-07 | 2026-02-17 | 浙江博锐生物制药有限公司 | 抗ror1抗体及其应用 |
| CN117467004B (zh) * | 2023-10-09 | 2024-06-21 | 武汉爱博泰克生物科技有限公司 | 抗人钙网膜蛋白的兔单克隆抗体及其应用 |
| CN122374334A (zh) * | 2023-11-15 | 2026-07-10 | 西雅图免疫公司 | 抗dll3抗体及其制备和使用方法 |
| CN117624355B (zh) * | 2023-11-30 | 2024-05-14 | 无锡傲锐东源生物科技有限公司 | 一种抗人乙酰化tau274兔单克隆抗体及其应用 |
| CN117736330B (zh) * | 2024-01-24 | 2024-05-17 | 上海沙砾生物科技有限公司 | 肿瘤坏死因子超家族受体9的特异性抗原结合蛋白及其应用 |
| WO2025217398A1 (en) | 2024-04-10 | 2025-10-16 | Lyell Immunopharma, Inc. | Methods for culturing cells with improved culture medium |
| CN118930648B (zh) * | 2024-08-22 | 2025-02-28 | 武汉爱博泰克生物科技有限公司 | 抗人pax8蛋白的兔单克隆抗体、抗体偶联物及其应用 |
| CN121851161B (zh) * | 2026-03-16 | 2026-05-08 | 南京诺唯赞医疗科技有限公司 | α-syn特异性抗体及其在帕金森辅助诊断试剂盒中的应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DE69624436T2 (de) * | 1995-04-08 | 2003-08-28 | Lg Chemical Ltd., Seoul/Soul | Humaner 4-1bb spezifischer humaner antikörper und diesen produzierende zellinie |
| KR20000034847A (ko) * | 1998-11-17 | 2000-06-26 | 성재갑 | 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물 |
| AU2002364935A1 (en) * | 2001-10-09 | 2003-06-23 | Mayo Foundation For Medical Education And Research | Enhancement of immune responses by 4-1bb-binding agents |
| AR046094A1 (es) * | 2003-10-10 | 2005-11-23 | Bristol Myers Squibb Co | Anticuerpos completamente humanos contra 4-1bb humano |
| US7288638B2 (en) * | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| EP1793857A4 (en) * | 2004-09-08 | 2008-09-03 | Univ Ohio State Res Found | COMBINED THERAPY USING ANTI-CTLA4 ANTI-4-1BB ANTIBODIES |
| KR100847755B1 (ko) * | 2006-03-29 | 2008-07-22 | 울산대학교 산학협력단 | 항-4-1ｂｂ 항체 및 항-ｃｄ4 항체를 포함하는 암 및자가면역질환 치료제 조성물 |
| KR20180005753A (ko) * | 2008-06-25 | 2018-01-16 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체 |
| AU2015252014B2 (en) * | 2009-04-23 | 2017-03-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-human ror1 antibodies |
| NZ729044A (en) * | 2010-09-09 | 2020-07-31 | Pfizer | 4-1bb binding molecules |
| AU2013201617B2 (en) * | 2010-09-09 | 2014-10-09 | Pfizer Inc. | 4-1BB binding molecules |
| EP2646469B1 (en) | 2010-12-01 | 2017-11-01 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Chimeric rabbit/human ror1 antibodies |
| GB201020995D0 (en) * | 2010-12-10 | 2011-01-26 | Bioinvent Int Ab | Biological materials and uses thereof |
| EP3252076B1 (en) * | 2011-01-14 | 2019-09-04 | The Regents Of The University Of California | Diagnostic use of antibodies against ror-1 protein |
| BR112014012819B1 (pt) * | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| PL3489261T3 (pl) * | 2012-08-24 | 2021-08-16 | The Regents Of The University Of California | Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu |
| CA2935748A1 (en) * | 2014-02-25 | 2015-09-03 | Immunomedics, Inc. | Humanized rfb4 anti-cd22 antibody |
| US10717783B2 (en) * | 2014-12-22 | 2020-07-21 | Zeren Gao | Bispecific tetravalent antibodies and methods of making and using thereof |
| CN104817642B (zh) * | 2015-05-04 | 2018-03-27 | 北京百普赛斯生物科技有限公司 | 抗人ror1单克隆抗体及其制备方法与应用 |
| EP3773621A4 (en) * | 2018-03-27 | 2022-03-23 | Systimmune, Inc. | GUIDANCE AND NAVIGATION CONTROL PROTEINS AND METHODS FOR THEIR MANUFACTURE AND USE |
-
2018
- 2018-06-22 EP EP18824588.0A patent/EP3645741A4/en active Pending
- 2018-06-22 EP EP26168987.1A patent/EP4793291A2/en active Pending
- 2018-06-22 EP EP18825285.2A patent/EP3645742B1/en active Active
- 2018-06-22 WO PCT/US2018/039155 patent/WO2019005638A2/en not_active Ceased
- 2018-06-22 JP JP2020520426A patent/JP7222987B2/ja active Active
- 2018-06-22 CN CN202310854150.8A patent/CN116925227A/zh active Pending
- 2018-06-22 JP JP2020520428A patent/JP7323513B2/ja active Active
- 2018-06-22 CN CN202310854013.4A patent/CN116731179A/zh active Pending
- 2018-06-22 ES ES18825285T patent/ES3075567T3/es active Active
- 2018-06-22 CN CN201880038385.7A patent/CN110799539B/zh active Active
- 2018-06-22 US US16/615,119 patent/US11987635B2/en active Active
- 2018-06-22 CN CN202310854068.5A patent/CN116731180A/zh active Pending
- 2018-06-22 CN CN202310929184.9A patent/CN116789832A/zh active Pending
- 2018-06-22 CN CN202310929014.0A patent/CN116769035A/zh active Pending
- 2018-06-22 US US16/615,116 patent/US11518815B2/en active Active
- 2018-06-22 CN CN201880038332.5A patent/CN110869389B/zh active Active
- 2018-06-22 WO PCT/US2018/039152 patent/WO2019005636A2/en not_active Ceased
-
2023
- 2023-02-03 JP JP2023015342A patent/JP7464764B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7685095B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| CN110799539B (zh) | 抗4-1bb抗体及其制备和使用方法 | |
| JP7399852B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| JP2020529863A5 (enExample) | ||
| JP2020501531A5 (enExample) | ||
| JP2020510422A5 (enExample) | ||
| JP7418326B2 (ja) | 二重特異性抗体並びにその製造方法及び使用方法 | |
| JP2018509175A5 (enExample) | ||
| JP2020529862A5 (enExample) | ||
| JP2023543493A5 (enExample) | ||
| JP2021501575A5 (enExample) | ||
| CN115461373A (zh) | 密蛋白18.2的抗体及其用途 | |
| JP2020530776A5 (enExample) | ||
| CN115916839A (zh) | 抗pdl1×egfr的双特异性抗体 | |
| JP2025514610A5 (enExample) | ||
| KR20220069961A (ko) | 항-cd371 항체 및 그의 용도 | |
| JP2019505545A5 (enExample) | ||
| JP2022502079A5 (enExample) | ||
| CN114829405A (zh) | 抗bcma/抗4-1bb双特异性抗体及其用途 | |
| EP4667491A1 (en) | Anti-cntn4 antibody and uses thereof | |
| RU2025136924A (ru) | Антитела против клаудина 18.2 и способы их получения и применения | |
| HK40097105A (en) | Bispecific antibodies and methods of making and using thereof | |
| RU2024126025A (ru) | Антитела против msln и способы их применения | |
| RU2025120667A (ru) | Антитела против pdl1 и способы их применения | |
| HK40018991A (en) | Multi-specific antibodies and methods of making and using thereof |